ReviewTranslational andrology and urology2018
Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.
Review in Translational andrology and urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis.Journal of cancer survivorship : research and practice · 2026Pooled it
- Oncological safety of active surveillance for low-risk ductal carcinoma in situ - a systematic review and meta-analysis.Irish journal of medical science · 2023Pooled it
- Radiomics vs radiologist in prostate cancer. Results from a systematic review.World journal of urology · 2023Pooled it
- Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review.European urology oncology · 2021Pooled it
- Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.European urology · 2018Pooled it
- Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.Asian journal of andrologyPooled it
- STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.BJU international · 2026Trial
- Impact of Clinicopathological and Institutional Factors on the Clinical Courses of Patients With Localized Prostate Cancer Initially Managed by Active Surveillance: An Analysis of Nationwide Real-World Data From Japan.International journal of urology : official journal of the Japanese Urological Association · 2026Observational
- The role of magnetic resonance imaging in the active surveillance of prostate cancer: state of the art.Abdominal radiology (New York) · 2026Review
- Active surveillance could apply to one-quarter of Korean prostate cancer cases: Insights from a 27,075-patient cohort.Prostate international · 2026Article
- mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active Surveillance.Cancers · 2026Article
- Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer.Journal of cancer research and clinical oncology · 2026Article
- Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study.Prostate cancer and prostatic diseases · 2026Article
- The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer.Cancers · 2026Article
- Circulating tumour DNA in mCRPC: bridging tumour biology and real-time treatment monitoring.Frontiers in molecular medicine · 2026Review
- A Randomised Clinical Trial Comparing Two Biopsy Templates and Follow-up Schedules for Men on Active Surveillance for Low-risk Prostate Cancer: SAMS.European urology open science · 2025Article
- Longitudinal MRI changes after focal therapy for prostate cancer: cryotherapy vs. microwave tissue coagulation.Japanese journal of radiology · 2025Article
- PACT is requisite for prostate cancer cell proliferation.Scientific reports · 2025Article
- Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.BJU international · 2025Article
- Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.BJU international · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-risk prostate cancer (PC), however there is discordance amongst large AS cohort studies with respect to entry and monitoring protocols. We systematically reviewed worldwide AS practices in studies reporting ≥5 years follow-up. We searched PubMed and Medline 2000-now and identified 13 AS cohorts. Three key areas were identified: (I) patient selection; (II) monitoring protocols; (III) triggers for intervention-(I) all studies defined clinically localised PC diagnosis as T2b disease or less and most agreed on prostate-specific antigen (PSA) threshold (<10 µg/L) and Gleason score threshold (3+3). Inconsistency was most notable regarding pathologic factors (e.g., number of positive cores); (II) all agreed on PSA surveillance as crucial for monitoring, and most agreed that confirmatory biopsy was required within 12 months of initiation. No consensus was reached on optimal timing of digital rectal examination (DRE), general health assessment or re-biopsy strategies thereafter; (III) there was no universal agreement for intervention triggers, although Gleason score, number or percentage of positive cancer cores, maximum cancer length (MCL) and PSA doubling time were used by several studies. Some also used imaging or re-biopsy. Despite consistent high progression-free/cancer-free survival and conversion-to-treatment rates, heterogeneity exists amongst these large AS cohorts. Combining existing evidence and gathering more long-term evidence [e.g., the Movember's Global AS database or additional information on use of magnetic resonance imaging (MRI)] is needed to derive a broadly supported guideline to reduce variation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.